Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorbitol + Tislelizumab + SOX in Locally Advanced Gastric Cancer
NCT06826079Phase 2Recruiting
- Start
- Nov 2024
- Primary completion
- Aug 2028
- Countries
- 1
01
Overview
Phase 2, randomised trial of sorbitol in gastric cancer (GC) and gastroesophageal junction adenocarcinoma (2 arms). Primary endpoints: Major Pathological Response, ypN0 rate and 1 more. Started Nov 2024; status: recruiting.
02
Drugs
sorbitol
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT06826079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06826079.